Surgical intervention, often followed by adjuvant radiation, chemotherapy, and endocrine therapy, constitutes the conventional approach, yet the complexity of breast cancer demands nuanced strategies, particularly in cases where resistance to estrogen receptor (ER) inhibition emerges during metastatic progression.3 The gene discussed is ESR1; the disease is breast carcinoma.